Co-Diagnostics Beats Estimates, Focuses on Regulatory Submissions

Co-Diagnostics reported third-quarter results with lower operating expenses and advanced FDA and Indian regulatory submissions for tuberculosis tests, highlighting regulatory and operational progress.